Insights into Early Stage of Antibiotic Development in Small and Medium-Sized Enterprises: A Survey of Targets, Costs, and Durations

Authors

Kevin Outterson, Boston Univeristy School of LawFollow
Christine Ardal, University of Oslo
Enrico Baraldi, Uppsala University
Ursula Theuretzbacher, Center for Anti-infective Agents, Vienna
Francesco Ciabuschi, Uppsala University
Jens Plahte, Norwegian Institute of Public Health
John-Arne Røttingen, Norwegian Knowledge Center for the Health Services

Author granted license

Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International

Document Type

Article

Publication Date

4-5-2018

ISSN

2052-3211

Publisher

Springer Nature

Language

en-US

Abstract

Antibiotic innovation has dwindled to dangerously low levels in the past 30 years. Since resistance continues to evolve, this innovation deficit can have perilous consequences on patients. A number of new incentives have been suggested to stimulate greater antibacterial drug innovation. To design effective solutions, a greater understanding is needed of actual antibiotic discovery and development costs and timelines. Small and medium-sized enterprises (SMEs) undertake most discovery and early phase development for antibiotics and other drugs. This paper attempts to gather a better understanding of SMEs’ targets, costs, and durations related to discovery and early phase development of antibacterial therapies.

Recommended Citation

Kevin Outterson, Christine Ardal, Enrico Baraldi, Ursula Theuretzbacher, Francesco Ciabuschi, Jens Plahte & John-Arne Røttingen, Insights into Early Stage of Antibiotic Development in Small and Medium-Sized Enterprises: A Survey of Targets, Costs, and Durations , in 11 Journal of Pharmaceutical Policy and Practice 8 (2018).
Available at: https://scholarship.law.bu.edu/faculty_scholarship/655